adenectomy and external radiation, there is no advantage in the procedure. However, of the patients with histologically proved pelvic node metastases, a third have survived five years, suggesting that the prognosis in this small group was favourably influenced by treatment.
The prognosis in endometrial cancer depends not only on the clinical stage of the disease, but also on the histological differentiation of the tumour. Roman et al. (1967) confirm the Oxford findings that more patients survive five years when the tumour is well differentiated. The response to therapy is also profoundly influenced by the extent of penetration of growth into the myometrium. A tumour with minimal invasion carries a good prognosis, whereas over 50% of patients with a tumour penetrating within 2 mm of the serosal surface have died. The low survival rate in patients with a poorly differentiated deeply invasive tumour is probably due to microscopic deposits of malignant cells in the regional lymphatics.
The risk of a patient having positive nodes is nil when the carcinoma is restricted to the endometrium, 2 1 % when the tumour penetrates 2 mm into the myometrium, 12-5 % with moderate depth of invasion and 41 % when the tumour penetrates to within 2 mm of the serosal surface. Similarly, the risk of a patient with a welldifferentiated growth (Broders Grade 1) having positive pelvic nodes is 10-2 %, with a moderately well-differentiated growth (Grades 2 and 3) 12% and with a poorly differentiated tumour (Grade 4) 25%.
The conclusion to be drawn is that the risk of unexpected metastases and a poor prognosis increases to high levels in poorly differentiated and deeply invasive tumours, even though the tumour is clinically restricted to the uterus. These patients, admittedly a small proportion of the total, cannot be cured by total hysterectomy and bilateral salpingo-oophorectomy; they must have additional therapy whether this be lymphadenectomy, external radiation, or a combination of the two.
On the basis of these figures, it is possible to formulate a policy in managing patients with endometrial carcinoma. If preliminary curettage reveals an anaplastic growth, the patient should be considered as a candidate for Wertheim's hysterectomy. If obesity or poor general health precludes extended surgery then supplementary external radiation from a high energy source should be given. If histological examination of a uterus removed by total hysterectomy reveals a growth which penetrates close to the serosal surface the prognosis should be guarded and the patients should be carefully followed up. They can also be treated with external radiation perhaps more efficiently when very high energy sources produced from a cyclotron or linear accelerator become more generally available for clinical use in the United Kingdom.
In our own series of patients we have been fortunate that there were no fistulae resulting from surgery but regrettably two patients died in the post-operative period from pulmonary emboli. These deaths occurred in spite of intensive postoperative physiotherapy with early mobilization and emphasize yet again the need to treat these women as high surgical risks.
Information is still being accumulated but we hope that this approach to the clinical management of patients with endometrial carcinoma will help to improve the prognosis even more. The characteristics of cells which are directly stimulated by cestrogen include a specific receptor molecule to which the circulating cestrogen becomes bound in the cytoplasm. Another different receptor protein exists in association with the cell nucleus. To this nuclear receptor the aestrogen is transferred from the cytoplasmic receptor before it produces its stimulatory effect. 'Target' cells must possess both receptors. Thus they are to be found in normal human endometrium but not in epithelium of the gut.
It has been shown (Brush et al. 1967a, b ) that human endometrium can take up administered cestrogen at all phases of the menstrual cycle but that in the luteal phase the proportion ofcestrogen which gains access to the cell being transferred to the nuclear receptor is much smaller than during the follicular phase of the cycle (Table 1 ). This Table 2 Uptake of [6, 7-H3] is an important effect of natural progesterone and it can be reproduced by synthetic progestational agents.
Studies involving the intravenous injection of [6, 7-H3] estradiol prior to operative treatment of various genital tract malignancies have given some interesting results ( Table 2 ). The mixed mesodermal tumour and the carcinosarcoma did take up some of the administered cestrogen, probably in a rather nonspecific way, for it was never transferred to the nuclear fraction of the tumour tissue. Squamous carcinoma of the vagina, adenocarcinoma of the endocervix and endometrium all took up cestrogen avidly and transferred a significant proportion to the nuclear fraction. These tumours unlike the sarcomata can justifiably be termed hormone-influenced if not hormone-dependent. The degree of differentia tion of the endometrial carcinoma did not appear to make any difference either to the uptake of administered cestrogen or to its intracellular distribution.
The use of pre-operative radiotherapy did not affect the ability of the tumour tissue to take up cestrogen or to fix it to the nuclear fraction of the cells. This is perhaps not surprising, as the main effect of radiotherapy on malignant cells at the stage these investigations were carried out -six weeks after radiotherapy -is on the chromosomes. It must be pointed out, too, that in 4 cases no tumour material remained for investigation after the administration of radiotherapy. It is possible, therefore, that the tumours studied were relatively radioresistant.
Two patients treated with progestational agents showed very satisfactory clinical responsecessation of bleeding and shrinkage of the tumour. In one case it ultimately disappeared completely. In spite of this the tumours retained their ability to take up and bind cestradiol to the cell nucleus. The normal fallopian tube epithelium in both cases showed obvious effects, both histologically and biochemically, of the progestational agents' effects. There was no good correlation between the tubal epithelium and the tumour as there always is between normal tubal epithelium and normal endometrium.
The findings in the cases pretreated with potent progestational agents are difficult to explain. It appears that there is a difference between normal target tissue and tumour tissue in their response, but the clinical effect was much better than might have been predicted from the effect on oestrogen uptake. This may indicate that the effect of progestational agents is not a simple anticestrogenic effect on the tumour but either a complex interference with cell metabolism or an effect involving depression of other potentially tumour-stimulating compounds.
